Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
Top Cited Papers
- 11 March 2010
- journal article
- review article
- Published by Elsevier in Health Policy
- Vol. 96 (3), 179-190
- https://doi.org/10.1016/j.healthpol.2010.02.005
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparatorBMJ, 2009
- The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the futureBMC Neurology, 2009
- The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicinesAustralia and New Zealand Health Policy, 2007
- Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?Internal Medicine Journal, 2006
- The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patientsHemodialysis International, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- No cure, no payBMJ, 2005
- Accelerated Approval of Oncology Products: A Decade of ExperienceJNCI Journal of the National Cancer Institute, 2004
- Shared scheme for assessing drugs for multiple sclerosis: Cost effective provision of effective treatments for multiple sclerosisBMJ, 2003
- Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary careBMJ, 2003